Dai 2005.

Methods	Allocation: randomised, no further detail. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient and outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more, CGI of 4 or more. N = 80. Age: aripiprazole group: 18～58 years. mean = (31 ± 8) years; quetiapine group: 19～57 years, mean = (32 ± 9) years. Gender: aripiprazole group: 20 male, 20 female; quetiapine group: 21 male, 19 female. History: aripiprazole group: 1 month～10 years, mean = (5.9 ± 3) years; clozapine group: 1 month～9 years, mean = (5 ± 3) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐30 mg/day. Mean dose: (23.3 ± 3.1) mg/day. N = 40. 2. Quetiapine: Dose range: 75‐700 mg/day. Mean dose: (565 ± 85) mg/day. N = 40.
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25). CGI average endpoint scale score. Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS general pathological subscale score. Adverse effects.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	No selective reporting.
Other bias	Low risk	None obvious.